STAT+
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Learn more.
Latest
STAT Plus: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse
STAT Plus: White House moves closer to a ban on menthol cigarettes, amid intensifying opposition from tobacco companies
STAT Plus: Teva sues Colorado over ‘unconstitutional’ program to lower cost of epinephrine injectors
STAT Plus: Pharmalittle: Rite Aid files for bankruptcy; Alzheimer’s brain scans get broader Medicare coverage
STAT Plus: Cell and gene therapy CEOs share survival strategies amid biotech slump
STAT Plus: FDA’s warning to J&J’s Abiomed signals a crackdown on digital health tools
STAT Plus: Dana-Farber’s divorce from Brigham is the culmination of decades of change
All Coverage
advertisement
